James C. Tsai

Last updated
James C. Tsai
JamesTsai-NYEE.jpg
Born1963
Education Amherst College, Stanford University School of Medicine, Owen Graduate School of Management at Vanderbilt University
Medical career
Profession Ophthalmologist
Institutions Vanderbilt University School of Medicine, Harkness Eye Institute at Columbia University College of Physicians and Surgeons, Yale University School of Medicine, New York Eye and Ear Infirmary of Mount Sinai, Icahn School of Medicine at Mount Sinai
Sub-specialties Glaucoma and glaucoma surgery
Website James C. Tsai at Mount Sinai

James C. Tsai is a physician and scientist who serves as president of the New York Eye and Ear Infirmary of Mount Sinai. [1] [2] [3] He also serves as the Delafield-Rodgers Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai and chair of the department of ophthalmology at the Mount Sinai Health System.

Contents

Tsai published the first taxonomy of medication compliance and adherence barriers in patients with glaucoma, the initial paper describing the isolated-check visual evoked potential technology for patients with glaucoma, [4] and one of the first studies evaluating the use of erythropoietin for neuroprotection in an animal model of glaucoma.

Biography

A 1981 graduate of Phillips Exeter Academy, Tsai received his B.A. in neuroscience, magna cum laude, from Amherst College in 1985, his M.D. from Stanford University School of Medicine in 1989, and his M.B.A. in 1998 from the Owen Graduate School of Management at Vanderbilt University. He served his residency in ophthalmology at Doheny Eye Institute at the University of Southern California, 1990–1993, his fellowship in glaucoma at Bascom Palmer Eye Institute, University of Miami, 1993–1994, and another fellowship in glaucoma at Moorfields Eye Hospital and the Institute of Ophthalmology, London, 1994–1995.

Former positions include assistant professor of ophthalmology and visual sciences and residency program director, department of ophthalmology and visual sciences at Vanderbilt University School of Medicine, [5] as well as associate professor of ophthalmology and director, glaucoma division, department of ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons. [1]

Tsai then served as the inaugural Robert R. Young Professor of Ophthalmology and Visual Science and chair, department of ophthalmology and visual science, Yale University School of Medicine [6] and chief of ophthalmology, Yale-New Haven Hospital. [7]

Research

Tsai's research includes the identification of neuroprotective molecules that can shield the optic nerve from damage without lowering intraocular pressure, evaluation of medical adherence and surgical outcomes in patients with glaucoma, and development of advanced vision testing techniques. [8]

His more recent research[ when? ] includes the long-term safety and efficacy of the Ahmed shunt versus the Baerveldt shunt implant, optimizing and enhancing medication adherence in patients with glaucoma, and understanding the role of inflammation in the pathogenesis and treatment of glaucoma. [9] [10] [11] [12]

Publications

Author of more than 100 peer-reviewed scientific articles and over 80 invited medical articles, book chapters, and textbooks, including the Oxford American Handbook of Ophthalmology and Medical Management of Glaucoma (4 editions). [13] [14] Tsai has served as editorial board member for 9 medical journals and manuscript reviewer for over 100 additional scientific publications.

His most cited journal articles are:

Related Research Articles

<span class="mw-page-title-main">Glaucoma</span> Group of eye diseases

Glaucoma is a group of eye diseases that lead to damage of the optic nerve, which is important for transmitting visual information from the eye to the brain. This damage is often caused by increased pressure within the eye, known as intraocular pressure (IOP) and may cause vision loss if left untreated. The word glaucoma originated from the Greek word ΓλαύV̇ξ (glaukos), which means "to glow". Glaucoma has been called the "silent thief of sight" because the loss of vision usually occurs slowly over a long period of time. It is associated with old age, a family history of glaucoma, and certain medical conditions or medications.

The National Eye Institute (NEI) is part of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The mission of NEI is "to eliminate vision loss and improve quality of life through vision research." NEI consists of two major branches for research: an extramural branch that funds studies outside NIH and an intramural branch that funds research on the NIH campus in Bethesda, Maryland. Most of the NEI budget funds extramural research.

<span class="mw-page-title-main">Radial keratotomy</span> Refractive surgical procedure to correct myopia (nearsightedness

Radial keratotomy (RK) is a refractive surgical procedure to correct myopia (nearsightedness). It was developed in 1974 by Svyatoslav Fyodorov, a Russian ophthalmologist. It has been largely supplanted by newer, more accurate operations, such as photorefractive keratectomy, LASIK, Epi-LASIK and the phakic intraocular lens.

<span class="mw-page-title-main">Optic nerve sheath meningioma</span>


Optic nerve sheath meningiomas (ONSM) are rare benign tumors of the optic nerve. 60–70% of cases occur in middle age females, and is more common in older adults. It is also seen in children, but this is rare. The tumors grow from cells that surround the optic nerve, and as the tumor grows, it compresses the optic nerve. This causes loss of vision in the affected eye. Rarely, it may affect both eyes at the same time.

<span class="mw-page-title-main">Superior limbic keratoconjunctivitis</span> Medical condition

Superior limbic keratoconjunctivitis is a disease of the eye characterized by episodes of recurrent inflammation of the superior cornea and limbus, as well as of the superior tarsal and bulbar conjunctiva. It was first described by F. H. Théodore in 1963.

A glaucoma valve is a medical shunt used in the treatment of glaucoma to reduce the eye's intraocular pressure (IOP).

<span class="mw-page-title-main">Iridodialysis</span> Medical condition

Iridodialysis is a localized separation or tearing away of the iris from its attachment to the ciliary body.

<span class="mw-page-title-main">New York Eye and Ear Infirmary</span> Hospital in New York, United States

Ultrasound biomicroscopy (UBM) is a type of ultrasound eye exam that makes a more detailed image than regular ultrasound.

Sohan Singh Hayreh was an ophthalmologist, clinical scientist, and professor emeritus of ophthalmology at the University of Iowa. As one of the pioneers in the field of fluorescein angiography, he was generally acknowledged to be a leading authority in vascular diseases of the eye and the optic nerve. For over 60 years, Hayreh was actively involved in basic, experimental, and clinical research in ophthalmology, publishing over 400 original peer-reviewed articles in various international ophthalmic journals, six classical monographs and books in his field of research, and more than 50 chapters in ophthalmic books. He made many seminal observations dealing with the ocular circulation in health and disease, the optic disc and the optic nerve, retinal and choroidal vascular disorders, glaucomatous optic neuropathy, fundus changes in malignant arterial hypertension, ocular neovascularization, rheumatologic disorders of the eye, and nocturnal arterial hypotension. He was an elected fellow of the National Academy of Medical Sciences.

<span class="mw-page-title-main">Canine glaucoma</span>

Canine glaucoma refers to a group of diseases in dogs that affect the optic nerve and involve a loss of retinal ganglion cells in a characteristic pattern. An intraocular pressure greater than 22 mmHg (2.9 kPa) is a significant risk factor for the development of glaucoma. Untreated glaucoma in dogs leads to permanent damage of the optic nerve and resultant visual field loss, which can progress to blindness.

Douglas Jabs is an American ophthalmologist and an expert in clinical research in the fields of ophthalmology and uveitis.

<span class="mw-page-title-main">Orbital lymphoma</span> Human disease of the eye

Orbital lymphoma is a common type of non-Hodgkin lymphoma that occurs near or on the eye. Common symptoms include decreased vision and uveitis. Orbital lymphoma can be diagnosed via a biopsy of the eye and is usually treated with radiotherapy or in combination with chemotherapy.

Sheraz Daya is a British ophthalmologist. Daya founded the Centre for Sight in 1996, and works in stem-cell research and sight recovery surgery.

Haab's striae, or Descemet's tears, are horizontal breaks in the Descemet membrane associated with congenital glaucoma. It is named after Otto Haab. These occur because descemet's membrane is less elastic than the corneal stroma. Tears are usually peripheral, concentric with limbus and appear as line with double contour.

Micro-invasive glaucoma surgery (MIGS) is the latest advance in surgical treatment for glaucoma, which aims to reduce intraocular pressure by either increasing outflow of aqueous humor or reducing its production. MIGS comprises a group of surgical procedures which share common features. MIGS procedures involve a minimally invasive approach, often with small cuts or micro-incisions through the cornea that causes the least amount of trauma to surrounding scleral and conjunctival tissues. The techniques minimize tissue scarring, allowing for the possibility of traditional glaucoma procedures such as trabeculectomy or glaucoma valve implantation to be performed in the future if needed.

Robert M. Schertzer is a Canadian ophthalmologist with a subspecialty in glaucoma treatment. He currently serves as the Clinical Associate Professor of Ophthalmology and Visual Sciences at the University of British Columbia.

Alon Harris is an American clinical scientist, professor of ophthalmology and Professor of Artificial Intelligence and Human Health, educator, inventor and researcher in the field of ocular blood flow and its relationship to diseases of the eye. Harris served as the principal or co-principal investigator on more than 60 research grants, published more than 392 peer-reviewed articles, and wrote 23 books and 70 book chapters. As of 2021, he holds two patents. Harris sits on the Board of Directors and the Scientific Advisory Board of The Glaucoma Foundation and is the Vice Chair of International Research and Academic Affairs, co-director of the Center for Ophthalmic Artificial Intelligence and Human Health at Mount Sinai Hospital, and Director of the Ophthalmic Vascular Diagnostic and Research Program at Icahn School of Medicine at Mount Sinai.

<span class="mw-page-title-main">Uveitic glaucoma</span> Glaucoma caused by uveitis or its treatments

Uveitic glaucoma is most commonly a progression stage of noninfectious anterior uveitis or iritis.

Cyclodestruction or cycloablation is a surgical procedure done in management of glaucoma. Cyclodestruction reduce intraocular pressure (IOP) of the eye by decreasing production of aqueous humor by the destruction of ciliary body. Until the development of safer and less destructive techniques like micropulse diode cyclophotocoagulation and endocyclophotocoagulation, cyclodestructive surgeries were mainly done in refractory glaucoma, or advanced glaucomatous eyes with poor visual prognosis.

References

  1. 1 2 "James C. Tsai Named President of New York Eye and Ear Infirmary of Mount Sinai" . Retrieved September 25, 2017.
  2. "Mount Sinai Launches Eye Research Institute" . Retrieved 25 September 2017.
  3. "Meet Our Doctors – The Advanced Center for Eyecare".
  4. Kent, Christopher (15 October 2006). "icVEP: A New Way to Catch Early Glaucoma?". Review of Ophthalmology. Retrieved 25 September 2017.
  5. "Faculty Profiles, Vanderbilt University" . Retrieved 25 September 2017.
  6. "Glaucoma Foundation: James C. Tsai, MD" . Retrieved 25 September 2017.
  7. "Yale Eye" (PDF). Retrieved 25 September 2017.
  8. "National Eye Institute" . Retrieved 25 September 2017.
  9. "Study compares drainage devices". Ophthalmology Times. 1 April 2012. Retrieved 14 September 2019.
  10. Tsai, James (June 2006). "The Ahmed Shunt versus the Baerveldt Shunt for Refractory Glaucoma II". Ophthalmology. 113 (6): 913–917. doi:10.1016/j.ophtha.2006.02.029. PMID   16751034.
  11. Dietrich, Mary S.; Kammer, Jeffrey A.; Johnson, Cameron Campbell; Tsai, James C. (2006). "The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma II: longer-term outcomes from a single surgeon". Ophthalmology. 113 (6): 913–7. doi:10.1016/J.OPHTHA.2006.02.029. PMID   16751034. S2CID   44825049.
  12. Sides Media, www sidesmedia com. "Glaucoma Today - When Tube Shunts Fail". Glaucoma Today. Retrieved 2019-09-14.
  13. Oxford University Press. Oxford American Handbooks of Medicine. Oxford University Press. 28 January 2011. ISBN   978-0-19-539344-6 . Retrieved 25 September 2017.
  14. Tsai, James C.; Forbes, Max (2009). Medical Management of Glaucoma. Professional Communications. ISBN   9781932610437 . Retrieved 25 September 2017.
  15. 1 2 3 4 5 Google Scholar author page. Accessed April 25, 2019